Skip to main content
Evidence Snapshot

Complement factor D

CHEMBL2176771 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:05:49Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2176771
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Complement factor D as ChEMBL target CHEMBL2176771, mapped to UniProt P00746. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Complement factor D
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2176771
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00746
Complement factor D
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Complement factor D matters

As of 2026-09-13

Complement factor D is reviewed as Complement factor D (UniProt P00746); Complement factor D shows approved-linked disease relevance led by acquired paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 4550 compounds, and 82 assays, with lead potency reaching pChEMBL 9.0.

Disease context
acquired paroxysmal nocturnal hemoglobinuria

Complement factor D shows approved-linked disease relevance led by acquired paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DANICOPAN.

Start review with acquired paroxysmal nocturnal hemoglobinuria because it currently carries approved-linked support. Linked drugs include DANICOPAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 4550 compounds, and 82 assays for this target. The dominant activity type is IC50. CHEMBL2180765 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL2180765 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 9.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Complement factor D matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00746, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why acquired paroxysmal nocturnal hemoglobinuria is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4550
Total Compounds
82
Total Assays
1
Approved Drugs
IC50: 6131.0, KI: 4.0, KD: 28.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2180765
 9.0 IC50 —
No preferred name
CHEMBL4106993
 9.0 IC50 —
No preferred name
CHEMBL4114217
 9.0 IC50 —
No preferred name
CHEMBL2180764
 8.7 IC50 —
No preferred name
CHEMBL3109655
 8.7 IC50 —

Approved Drugs

Structure Compound First Approval
DANICOPAN
CHEMBL4250860
 2024
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:05:49Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2176771